Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035828 · ClinicalTrials.gov registry record · Phase 2
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
A Phase 2 study of Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic, sponsored by Abgenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00035828: Completed Phase 2 study of Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic, sponsored by Abgenix.
NCT00035828 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic that has completed, run by Abgenix. The registered enrollment target is 150 participants, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035828, a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic, has completed, sponsored by Abgenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if ABX-IL8 will improve shortness of breath.
Conditions Studied
Interventions
- DRUG ABX-IL8
Study Locations (1)
California
- Abgenix - Fremont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-12 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
What the finished NCT00035828 record still lists
NCT00035828 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which ABX-IL8 is the first listed.
NCT00035828 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00035828 about?
NCT00035828 is a clinical study titled "A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD". To determine if ABX-IL8 will improve shortness of breath.
What is the current status of trial NCT00035828?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2001-12. Estimated completion is 2002-12.
What conditions does trial NCT00035828 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic.
What interventions are being tested in trial NCT00035828?
The interventions under investigation include: ABX-IL8 (DRUG).
Who is sponsoring clinical trial NCT00035828?
This trial is sponsored by Abgenix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035828 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00035828's enrollment target sits among peer trials
150 49th of 74 higher than 26 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia